Infographic | June 14, 2022

Drug Innovators' Outlook On Innovative Treatments

Source: ISR Reports

In Q32021, ISR asked 134 outsourcers of biologic drug substance to provide a little insight into their pipelines and how that might impact their outsourcing practices. Two-thirds (63%) of respondents agree – strongly agree that their company’s focus on new, innovative treatments will impact their outsourcing practices. Roughly one-third of respondents confirmed ADC (37%) and CAR-T (30%) therapies are areas of focus.

access the Infographic!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)

ISR Reports